John Francis Seymour

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

2011 | Lékařská fakulta v Hradci Králové

Publikace